Teriparatide hmoov CAS No.52232-67-4

Teriparatide tsuas yog cov pob txha pom zoo- ua tus neeg sawv cev, feem ntau yog siv los kho cov neeg mob osteoporosis uas muaj kev pheej hmoo ntawm pob txha. Nws lub luag haujlwm tseem ceeb yog txhawm rau txo qhov kev pheej hmoo ntawm vertebral thiab tsis yog -vertebral fractures los ntawm kev txhawb nqa cov pob txha tshiab, txhim kho pob txha ceev thiab pob txha muaj zog. Nws yog qhov tshwj xeeb tshaj yog rau cov neeg mob uas tsis muaj txiaj ntsig lossis ua tsis taus rau cov tshuaj tiv thaiv ib txwm muaj -resorptive xws li bisphosphonates.

1. Ua kom cov osteoblasts:

Kev txhaj tshuaj tsis tu ncua ntawm teriparatide tuaj yeem ua rau osteoblasts (pob txha- tsim cov hlwb), txhawb cov pob txha matrix synthesis thiab mineralization, thiab nce pob txha ceev.

2. Inhibition ntawm kev ua haujlwm osteoclast:

Kev siv luv luv -lub sij hawm siv tau me ntsis inhibit osteoclast kev ua, txo cov pob txha resorption, tab sis ntev - cov nyhuv tseem tseem txhawb kev tsim cov pob txha.

3. Kev tswj cov calcium thiab phosphorus metabolism:

Los ntawm stimulating calcium reabsorption nyob rau hauv lub raum thiab calcium tso tawm ntawm cov pob txha, nws tswj cov ntshav calcium, tab sis calcium thiab vitamin D supplementation yuav tsum tau ua ke kom tsis txhob hypocalcemia.

请替换当前 的更多内容

请替换当前 的更多内容

1. Cov lus qhia:

• Postmenopausal osteoporosis nyob rau hauv cov poj niam (tshwj xeeb yog cov neeg uas muaj keeb kwm ntawm pob txha los yog cov uas muaj kev pheej hmoo siab ntawm pob txha).

• Txiv neej osteoporosis.

• Osteoporosis induced los ntawm glucocorticoids (osteoporosis tshwm sim los ntawm ntev - siv cov tshuaj hormones).

2. Cov Lus Qhia Tshwj Xeeb:

• Rau cov neeg mob uas tau ua tsis tau tejyam kev kho mob yav dhau los los yog xav tau kev txhim kho cov pob txha ceev (xws li cov pob txha tsis ntev los no).

• Qee lub teb chaws / cheeb tsam tau pom zoo rau nws rau cov kab mob tsis tshua muaj keeb kwm ntawm cov pob txha xws li X-txog hypophosphatemic rickets.

1. Kev txhawb nqa pob txha:

• Tom qab 12-18 lub hlis ntawm kev kho mob, vertebral pob txha ceev tuaj yeem nce 6-12%, thaum cov pob txha tsis muaj pob txha tuaj yeem nce 2-4%.

• Txo qhov kev pheej hmoo ntawm pob txha pob txha (kwv yees li 65%) thiab tsis muaj pob txha pob txha (kwv yees li 20%).

2. Synergy nrog lwm yam tshuaj:

• Tom qab txiav tawm, nws raug nquahu kom hloov mus rau cov tshuaj tiv thaiv pob txha resorption (xws li bisphosphonates thiab denosumab) kom muaj pob txha ceev.

• Kev siv ua ke nrog calcium thiab vitamin D tuaj yeem txhim kho kev kho mob thiab txo qhov kev pheej hmoo ntawm hypocalcemia.

1. Muaj peev xwm txaus ntshai:

Osteosarcoma risk: Long term use (>24 lub hlis) hauv kev sim tsiaj yog txuam nrog osteosarcoma, tab sis tib neeg cov ntaub ntawv raug txwv, thiab FDA pom zoo kom siv tsis pub dhau 24 lub hlis.

Hypocalcemia: Nws yog ib qho tsim nyog los saib xyuas cov ntshav calcium thiab ntxiv calcium thiab vitamin D yog tias tsim nyog.

2. Lwm yam kev mob tshwm sim:

Feem ntau: mob taub hau, xeev siab, qhov chaw txhaj tshuaj (redness, o, mob).

Tsis tshua muaj: Hypercalcemia (yuav tsum tau saib xyuas cov ntshav calcium thiab lub raum ua haujlwm).

Lub teriparatide muab los ntawmXi'an Tihealth Biotechnology Co., Ltd.yog tus cwj pwm los ntawm kev purity siab, kev ruaj ntseg siab thiab ua raws li cov qauv thoob ntiaj teb, thiab yog ib qho tseem ceeb raw khoom hauv kev kho mob pob txha. Los ntawm kev tshawb fawb soj ntsuam cov tshuaj pharmacological thiab kev tswj hwm nruj, nws muab kev lees paub txhim khu kev qha rau kev txhim kho cov neeg mob thiab kev npaj cov davhlau ya nyob twg.